Marcelo V Negrao - JoVE Visualize

Showing results (11-20 of 58) with videos related to

Pageof 6

Sort By:

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2020

STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase InhibitionPiyada Sitthideatphaiboon, Ana Galan-Cobo, Marcelo V Negrao, et al.

The Annals of Thoracic Surgery|September 25, 2019

Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung CancerKyle G Mitchell, Marcelo V Negrao, Edwin R Parra, et al.

JCO Precision Oncology|December 27, 2021

Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 SkippingXiuning Le, Lingzhi Hong, Chuck Hensel, et al.

The Oncologist|August 8, 2020

Adjuvant Treatment with 5-Fluorouracil and Oxaliplatin Does Not Influence Cardiac Function, Neurovascular Control, and Physical Capacity in Patients with Colon CancerRaphaela V Groehs, Marcelo V Negrao, Ludhmila A Hajjar, et al.

JTO Clinical and Research Reports|March 17, 2023

Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-Resistant Advanced NSCLCMarcelo V Negrao, Vassiliki A Papadimitrakopoulou, Andrew C Price, et al.

Journal of the American Heart Association|February 23, 2021

Breast Cancer Promotes Cardiac Dysfunction Through Deregulation of Cardiomyocyte Ca2+-Handling Protein Expression That is Not Reversed by Exercise TrainingTassia S R da Costa, Ursula Urias, Marcelo V Negrao, et al.

American Journal of Physiology. Heart and Circulatory Physiology|September 8, 2023

Sympathetic neural overdrive and diminished exercise capacity in reduced ejection fraction heart failure related to anthracycline-based chemotherapyAmanda G Rodrigues, Allan R K Sales, Diego Faria, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2019

PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung CancerMarcelo V Negrao, Vincent K Lam, Alexandre Reuben, et al.

Future Oncology (London, England)|April 6, 2026

SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLCSolange Peters, Maximilian Hochmair, Kathryn C Arbour, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2025

Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung CancerMelissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.

Pageof 6

Showing results (11-20 of 58) with videos related to

Sort By:

Pageof 6

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2020

STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase InhibitionPiyada Sitthideatphaiboon, Ana Galan-Cobo, Marcelo V Negrao, et al.

The Annals of Thoracic Surgery|September 25, 2019

Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung CancerKyle G Mitchell, Marcelo V Negrao, Edwin R Parra, et al.

JCO Precision Oncology|December 27, 2021

Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 SkippingXiuning Le, Lingzhi Hong, Chuck Hensel, et al.

The Oncologist|August 8, 2020

Adjuvant Treatment with 5-Fluorouracil and Oxaliplatin Does Not Influence Cardiac Function, Neurovascular Control, and Physical Capacity in Patients with Colon CancerRaphaela V Groehs, Marcelo V Negrao, Ludhmila A Hajjar, et al.

JTO Clinical and Research Reports|March 17, 2023

Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-Resistant Advanced NSCLCMarcelo V Negrao, Vassiliki A Papadimitrakopoulou, Andrew C Price, et al.

Journal of the American Heart Association|February 23, 2021

Breast Cancer Promotes Cardiac Dysfunction Through Deregulation of Cardiomyocyte Ca2+-Handling Protein Expression That is Not Reversed by Exercise TrainingTassia S R da Costa, Ursula Urias, Marcelo V Negrao, et al.

American Journal of Physiology. Heart and Circulatory Physiology|September 8, 2023

Sympathetic neural overdrive and diminished exercise capacity in reduced ejection fraction heart failure related to anthracycline-based chemotherapyAmanda G Rodrigues, Allan R K Sales, Diego Faria, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2019

PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung CancerMarcelo V Negrao, Vincent K Lam, Alexandre Reuben, et al.

Future Oncology (London, England)|April 6, 2026

SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLCSolange Peters, Maximilian Hochmair, Kathryn C Arbour, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2025

Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung CancerMelissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.

Pageof 6